Cooperative Agreement UG3HL173303
Award Date
5/15/24
Completion Date
4/30/31
Dollars Obligated
$359K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.837
Assistance Type
Cooperative Agreement
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,397,921 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Triangle Institute (RTI International) to conduct the 2/2 Neonatal Platelet Transfusion Threshold Trial (NEOPLATT). This multi-year study aims to evaluate optimal platelet transfusion thresholds for extremely preterm infants at high risk of intracranial hemorrhage. The University of Colorado-Denver has been awarded a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $888,496 in funding to Versiti Wisconsin, Inc. to conduct research on fetal/neonatal alloimmune thrombocytopenia (FNAIT). The award, spanning from May 1, 2024, to April 30, 2028, aims to determine whether severe bleeding and other pregnancy complications associated with FNAIT are caused by specific antibodies that impair the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $5,154,906.00 to Versiti Wisconsin, Inc. and the Children's Hospital of Philadelphia (CHOP) to conduct a multi-disciplinary investigation of molecular mechanisms underlying immune-mediated thrombocytopenic and thrombotic disorders. The central focus is to build a deeper understanding of clinically relevant immunological insults...
The University of Colorado-Denver was awarded a Project Grant of $225,600.00 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will support the development of a "lab-on-a-particle" platform to measure platelet function and identify new patterns of underlying bleeding disorders. The project aims to create an innovative diagnostic approach that incorporates key elements of platelet function, including...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $764,817 to the University of North Carolina at Chapel Hill to investigate the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The research aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/annexin A2 and urokinase-type plasminogen activator pathways, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $375,988 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The award, effective May 20, 2024 through December 1, 2026, will support research to examine the interactions between mutant endothelial cells and mural cells/macrophages in capillary malformations, a common vascular disorder. The project aims to provide new...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $391,250 to Emory University for a project investigating fibrinogen as a potential mediator of COVID-19-associated coagulopathy. The primary objectives are to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well as to examine the role of a specific fibrinogen...
This federal Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $513,984 to Emory University to expand the Southeast Bone Marrow Transplant Consortium (SE-BMT). The award aims to design and develop innovative clinical trials for hematopoietic stem cell and cell-based therapies to address the medical needs of patients with cancer, hemoglobinopathies, and marrow failure. It will also...
This Project Grant award, valued at $125,658, was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award will support research to unravel the mechanisms by which dietary saturated fatty acids (SFAs) influence platelet function and thrombosis in obesity.
The key objectives are to: 1) Determine how fatty acid uptake affects platelet membrane composition, 2) Assess the impact of dietary SFAs on platelet...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $445,000 and will fund research to characterize the role of neutrophil extracellular traps (NETs) in immune homeostasis and investigate the potential of NET-directed therapeutics in sepsis and sickle cell disease.
The research aims to fill knowledge gaps in understanding the protective and detrimental effects of NETs, and to define the...